Cas:114144-16-0 6-iodoindoline manufacturer & supplier

We serve Chemical Name:6-iodoindoline CAS:114144-16-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-iodoindoline

Chemical Name:6-iodoindoline
CAS.NO:114144-16-0
Synonyms:1H-Indole,2,3-dihydro-5-iodo;5-iodoindoline;6-IODO-2,3-DIHYDRO-1H-INDOLE;2,3-dihydro-5-iodoindole;5-iodo-2,3-dihydro-1H-indole
Molecular Formula:C8H8IN
Molecular Weight:245.06000
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:289.617ºC at 760 mmHg
Density:1.794 g/cm3
Index of Refraction:1.654
PSA:12.03000
Exact Mass:244.97000
LogP:2.39720

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1H-Indole,2,3-dihydro-5-iodo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-iodo-2,3-dihydro-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dihydro-5-iodoindole Use and application,5-iodoindoline technical grade,usp/ep/jp grade.


Related News: Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 6-iodoindoline manufacturer But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. 6-iodoindoline supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). 6-iodoindoline vendor Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 6-iodoindoline factory The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.